Zim Laboratories Ltd
Zim Laboratories Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Zim Laboratories Ltd's next results in your feed
Guidance rank: #34 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Zim Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Export revenue in Q2 FY27: ₹908 Mn, up 24.7% YoY; Domestic revenue: ₹128 Mn, flat YoY.
As stated in Zim Laboratories Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Zim Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10). Q2 FY27 EBITDA: ₹77 Mn, down 1.2% YoY from ₹78 Mn.
From Zim Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Zim Laboratories' revenue grow in the September 2026 quarter?
- Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10).
- Export revenue in Q2 FY27: ₹908 Mn, up 24.7% YoY; Domestic revenue: ₹128 Mn, flat YoY (Page 16).
- Innovative Product revenue (NIP + OTF) in Q2 FY27: ₹149 Mn, growing 84% YoY, contributing 14% to total operating income (Page 15).
2 more points from Zim Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Zim Laboratories' margins in Q2 FY27?
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Zim Laboratories planning?
- Capital expenditures primarily focused on infrastructure, equipment, BE studies, and registrations; ₹45 Mn allocated in Q2 FY27 for BE studies and regulatory filings (Page 19).
- Total Capex / gross block increased over years: ₹4,188 Mn in H1 FY27, up from ₹2,257 Mn in FY23, reflecting ongoing investments (Page 21).
- New Cephalosporin plant commissioned; old plant production stopped and costs being rationalized (Page 6).
- Old Unit 3 for nutraceuticals shut down; production shifted to new nutraceutical facility to optimize costs (Page 6).
- Around ₹180 Mn spent over past 15 months on EU GMP remediation (one-time, not recurring) (Page 10).
2 more points from Zim Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Zim Laboratories raising money or cutting debt?
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Zim Laboratories' order book?
See what Zim Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Zim Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹94 Cr, net loss ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
- Aurobindo Pharma (Q2 FY27)
Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13). Key investor presentation takeaways from Aurobindo Pharma Ltd's Q2 FY27 investor present
- SMS Pharmaceuticals (Q2 FY27)
Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6). Key investor presentation takeaways
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zim Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zim Laboratories Ltd Q2 FY27 results?
Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10). Q2 FY27 EBITDA: ₹77 Mn, down 1.2% YoY from ₹78 Mn.
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 195.0 with a market cap of ₹721 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
Capital expenditures primarily focused on infrastructure, equipment, BE studies, and registrations; ₹45 Mn allocated in Q2 FY27 for BE studies and regulatory filings (Page 19).
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.